TAVR in Adults With Pure Severe Aortic Regurgitation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

76 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-01

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aimed to evaluate the efficacy and safety of transcatheter aortic valve replacement (TAVR) in patients with severe native valve aortic insufficiency. It is a multicentre, observational cohort study. The primary endpoint consisted of a composite of all-cause death, disabling stroke, or rehospitalization for heart failure at 12 months postoperatively. According to previous research results and opinions of expert groups, the sample size was expected to be 76 cases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation

NCT06381271

Aortic Valve Regurgitation

RECRUITING

TAVR for Aortic Valve Disease

NCT05439863

Aortic Valve Disease

RECRUITING

TAVR With Echocardiography Guidance

NCT07035847

Aortic Stenosis

RECRUITING NA

Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in "Real World" Chinese Patients

NCT06257043

Aortic Valve Disease Mixed

RECRUITING

Randomized Study for the Optimal Treatment of Symptomatic Patients With Low Gradient Severe Aortic Valve Stenosis and Preserved Left Ventricular Ejection Fraction

NCT03667365

Aortic Valve Stenosis

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transcatheter Aortic Valve Replacement Aortic Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAVR group

The group that undergoes transcatheter aortic valve replacement

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 60 years;
* Patients with severe aortic regurgitation (\> grade 3) diagnosed by transthoracic echocardiography should meet any of the following conditions for semi-quantitative assessment of the degree of aortic regurgitation and any condition for quantitative assessment of the degree of aortic regurgitation: (1) semi-quantitative assessment of the degree of aortic regurgitation: aortic regurgitation bundle width/left ventricular outflow tract diameter ≥ 65%; or aortic regurgitation neck width \> 6 mm; or full-diastolic blood flow reflux in the proximal abdominal aorta; (2) quantitative assessment of the degree of aortic regurgitation: aortic regurgitation volume ≥ 60 ml/beat; or aortic regurgitation fraction ≥ 50%; or effective regurgitation orifice area ≥ 0.3 cm2
* TAVR has been performed;
* Patients can understand and voluntarily participate in this clinical study, sign informed consent, and adhere to clinical follow-up.

Exclusion Criteria

* History of aortic valve replacement;
* Combined with moderate-severe mitral regurgitation and moderate aortic stenosis;
* Acute endocarditis or other acute cardiac inflammation;
* Allergic or contraindicated to related drugs (aspirin, clopidogrel, warfarin, contrast agent);
* Other conditions judged by the investigator as not suitable for the study

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No